Vaximm, an OSR Company, Receives Binding Term Sheet from BCM Europe for Global Exclusive License of VXM01 with $30M Upfront and Up to $815M in Milestones

Core Viewpoint - OSR Holdings, Inc. announced that its Swiss biotechnology subsidiary, Vaximm AG, has received a binding term sheet from BCM Europe AG for a global exclusive licensing transaction for VXM01, Vaximm's lead immunotherapy candidate [1][2] Group 1: Licensing Agreement Details - BCM Europe intends to establish a dedicated investment vehicle, BCM Decentralized Science Investors I, LP, which will act as the Licensee under the proposed licensing agreement [2] - The agreement includes an upfront payment of $30 million, structured as 50% cash and 50% digital assets, and aggregate milestone payments of up to $815 million, primarily focused on clinical and development achievements [7] - A royalty pass-through structure will allow the Fund to pass through royalty revenues from a future sublicensee or commercial partner to Vaximm, with a reconciliation mechanism for milestone payments [7] Group 2: Clinical and Market Potential - VXM01 has shown encouraging clinical and safety data across multiple indications, indicating its potential value as a differentiated immunotherapy asset [3] - The binding term sheet reflects third-party confidence in VXM01's value and the intent of BCM Europe to close the deal [4] - If the licensing agreement is completed, it would provide a strong foundation for advancing VXM01 into later-stage development while preserving long-term upside for Vaximm [3] Group 3: Company Background - OSR Holdings, Inc. is a global healthcare holding company focused on advancing biomedical innovations in healthcare and wellness, engaging in immuno-oncology, regenerative biologics, and medical device technologies [5] - Vaximm AG is a privately held Swiss-German biotechnology company that utilizes a proprietary orally administered T-cell vaccination platform to induce robust cellular immune responses [6] - BCM Europe AG is a Switzerland-based life sciences investment entity and the largest shareholder of OSR Holdings [8]